Vector in Biological Technology
Navigation Links
Vector in Biological Technology
Cynvec to Present at The 2009 New York Venture Summit
... CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly ... Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real ... CYN 101 in the third quarter of 2009. The sindbis vector has demonstrated in vivo efficacy delivering a ...... titled "Cynvec: Breakthrough Oncolytic Viral vector Therapy with Sindbis" at the 11th Annual Shanghai ... CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly ... Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real ...
Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
... CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly ... Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real ... cancer in the third quarter of 2009. The sindbis vector has also demonstrated in vivo efficacy delivering ...Cynvec to Present at the BIO National Venture Conference
... CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly ... Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real ... cancer in the third quarter of 2009. The sindbis vector has also demonstrated in vivo efficacy delivering ...GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools
... reagents and tools. They include 1) miExpress(TM) vector based precursor miRNA expression clones; 2) ... RT-qPCR system. Constructed in a lentiviral vector system, miExpress(TM) precursor miRNA expression ... mouse (450), and rat (270). These lentiviral vector based expression constructs allow efficient ...Virginia Tech researchers discover how mosquitoes avoid succumbing to viruses they transmit
... small RNAs modulate pathogenesis in disease vector mosquitoes," by Myles; Michael R. Wiley of ... a mosquito called Aedes aegypti, an important vector of yellow fever and dengue. In response, the ... a virus that is transmitted by an arthropod vector , said Myles. The researchers used an Illumina ...Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
... "By using oral delivery of a non- replicating vector with a potent adjuvant, we achieve a ... Vaxart platform is the ability to employ the same vector (delivery vehicle) across all vaccines. Typically ... less effective, because the body neutralizes the vector before a response can be mounted against the ...Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
... Lentigen will apply its proprietary lentiviral vector (LV) technology to the development of ... us to extend the application of our lentiviral vector technology to a wider range of diseases while ... company focused on the development of lentiviral vector technology for a wide range of therapeutic, ...... damaged DNA. A specially designed lentiviral vector will be used to deliver the gene specifically to ... step towards our goal of applying our lentiviral vector expertise to the development of ... and stability. By comparison, other viral vector systems such as non-viral, adenoviral and ...
On the trail of rogue genetically modified pathogens
... markers that can distinguish between artificial vector sequences and natural DNA sequences. Natural plasmids and artificial vector sequences have much in common, but these new ... and viruses. The tool clusters the artificial vector sequences into different subgroups based on ...VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
... are proving the effectiveness of our lentiviral vector approach in attacking HIV," said Dr. Laurent Humeau, VP of R&D for VIRxSYS. "Our lentiviral vector VRX496 appears to sustain expression of the RNA ... of this disease." VRX496 is a different viral vector than those used in previous gene therapy trials. ...Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
... of GBP IP with this premiere set of lentiviral vector intellectual property assets from Cell Genesys," ... and commercialize Cell Genesys' lentiviral vector IP estate," commented Lentigen's Founder and CEO Dr. Boro Dropulic. "Lentiviral vector technology has enormous potential as research and ...... Disease CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin, a naturally occurring protein known to ... delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in a multi-center, ...
Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
... the pandemic strain into Vaxart's pre-constructed vector. Vaxart's vector grows quickly and reproducibly in cell culture using a standard process. ... under development. Vaxart has shown that prior exposure to their platform vector does not impact the performance of later vaccinations. The company has ...Atritech Completes $30 Million Financing
... Partners and insider investments from Prism Ventures, Tullis-Dickerson and vector Group. Over the past 3 years, the Company has raised approximately $75 ... Venture Partners, Thomas McNerney Partners, Tullis-Dickerson Partners, The vector Group, Thoma Cressey Funds, SightLine Funds and Affinity Capital. For more ...Cynvec LLC(SM) to Present at the Cowen and Company 29th Annual Health Care Conference
... with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. ... of CYN 101 in ovarian cancer in the third quarter of 2009. The sindbis vector has also demonstrated in vivo efficacy delivering a variety of cytokines ...Genetic information personalizes warfarin prescribing
... older technique called linear regression and a newer one called support vector regressionwere equally successful when a combination of clinical ... for it because it's much easier to understand and use than the support vector regression model," says Page, noting that the program is easily accessed ...Imugene and Merial Establish Strategic Alliance
... and drugs. Imugene owns the worldwide rights to the Fowl Adenoviral vector Delivery System for poultry and the Porcine Adenoviral vector Delivery System for pigs. For more information please visit the ...Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
... CERE-120 CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known ... delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is about to enter a Phase 2 study for ...... be at risk for recurrence." Reximmune-C is a tumor-targeted gene delivery vector delivering an immune-stimulating cytokine gene directly to residual ... the preclinical studies, pilot clinical studies, and the elegant vector design engineering embodied in Reximmune-C, which make this clinical ...
... Andrew Davidoff, M.D., and John Gray, Ph.D., in developing a novel AAV vector that produces therapeutic levels of Factor IX when given intravenously in animal models. This vector has been licensed to AMT. Repair factor IX production and blood ...
Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
... of approximately 160,000 previously-cloned lentiviral-based shRNA vector constructs. Currently, more than 5,000 clones have been tested in the ... will eventually comprise 300,000 pre-cloned lentiviral-based shRNA vector constructs targeting the human and mouse genomes. Sigma-Aldrich's ...Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
... "Lentigen are the ideal partner for this piece of fundamental lentiviral vector technology. We are pleased to be working with a team committed to ... owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research ...... cell lines by transforming the cell line of choice to stably express vector or gene of interest. Optional cloning and shRNA expression services are ... -- Assay development and library screening -- Cloning and plasmid vector construction -- Generation of stable cell lines -- RNAi experiments ...
... delivery that allows for localized control of gene uptake. The Gene Activated Matrix comprises any biocompatible matrix containing a gene or DNA vector encoding for a growth factor or any therapeutic protein. The Gene Activated Matrix technology allows for a broad spectrum of formulations and the ...
... by Clavis Pharma. About Clavis Pharma Clavis Pharma ASA is an oncology focused pharmaceutical company using its proprietary Lipid vector Technology (LVT) platform to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved ...
... over the coming years. About Clavis Pharma Clavis Pharma ASA is an oncology focused pharmaceutical company using its proprietary Lipid vector Technology (LVT) platform to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved ...
... final data set is (p=0.006). There were no major clinically meaningful imbalances in baseline characteristics in the PROSTVAC(TM) and control vector treated arms. PROSTVAC(TM) immunotherapy was well tolerated, with some patients having injection site reactions (40-60%), and systemic ...
ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
... GTU(R) MultiHIV DNA plasmid with IVT's DepoVax(TM) vaccine delivery system to advance a therapeutic HIV vaccine. "DepoVax(TM) will act as a vector to deliver FIT Biotech's GTU(R) MultiHIV DNA vaccine and our goal is to develop a more sophisticated and efficient HIV vaccine candidate," commented ...... strain of the company's core technology, MVA-BN(R), which is the basis for its smallpox vaccine, IMVAMUNE(R). MVA-BN(R) also holds promise as a vector for delivering recombinant vaccines. Bavarian Nordic has asserted four US patents as a basis for its infringement action. The claim in this case is ...
... and left ventricular function/remodeling (5 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters. "This peer reviewed publication of our results further validates our target and approach and we ...
Energy Leaders Gather in Houston; Call for Balanced, Careful Approach to Energy Policy
... American Biofuels Council; Steve Winn, CEO, Nuclear Innovation North America LLC; Kevin Howell, President, NRG Texas; Brett Perlman, President, vector Associates; and Mark Kapner, Senior Strategy Planner, Austin Energy. Video of the event will soon be made available on www.houston.org and at ...DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors
... of synthetic genes. DNA2.0 will continue to develop new vectors with additional features in order to provide customers with the most advanced vector technology available. "DNA2.0's pJexpress vectors routinely express protein more efficiently than traditional pET vectors and without IP ...GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
... developer of the vaccine and GeoVax's Vice President of Research and Development, also presented these same results at the Viral vector Vaccines 2008 meeting, at the Wellcome Trust Conference Center near Cambridge, U.K., on September 28, 2008. * Phase 2a Preventive ...Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
... need." About Lentigen Corporation Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are the most ...Bavarian Nordic's Case Against Oxford BioMedica
... strain of the company's core technology, MVA-BN(R), which is the basis for its smallpox vaccine, IMVAMUNE(R). MVA-BN(R) also holds promise as a vector for delivering recombinant vaccines. Bavarian Nordic has asserted three US patents as a basis for its infringement action. The claim in this case is ...... elevate drooping cheeks, chin, or eye brows. The difference of the Frame Thread Lift procedure as opposed the Contour Lift is that Dr. Woo Jung Ho's vector technique creates a "frame" on the face. The frame effect supports the structure and tissues--from low to high. There have been more than a ...
TRIDELITY Display Solutions Partners With Two Of The World's Leading Imaging Software Companies
... and powerful tools to satisfy the most demanding needs in image data analysis, optical or electron microscopy imaging, molecular simulation, vector and flow visualization, and finite element modeling. "For a long time we were in doubt whether autosterescopic 3D display technology can ...... as standalone oncolytic therapeutics, delivery systems for monoclonal antibodies and cytokines as well as cancer diagnostic products. The Sindbis vector system, originally developed at NYU School of Medicine, represents a unique, patented platform technology for numerous commercial applications. The ...
... as standalone oncolytic therapeutics, delivery systems for monoclonal antibodies and cytokines as well as cancer diagnostic products. The Sindbis vector system, originally developed at NYU School of Medicine, represents a unique, patented platform technology for numerous commercial applications. The ...
Other ContentspinwormspinwormdwarfismplaceboplaceboplaceboplacebopreviapreviaOther Tagshighlighthighlighthighlighthighlight
(Date:11/23/2009)... CHAMPAIGN, Ill. A new study provides "incontrov... of Toba on the island of Sumatra about 73,000 yea...0 miles from the epicenter, researchers report. ,...eters of ash into the atmosphere, leaving a crater...00 kilometers long and 35 kilometers wide. Ash fro...
(Date:11/23/2009)..., BIRMINGHAM, Ala. A new study by University of...t body-mass index (BMI) and co-existing medical co...ed survival observed among African-Americans compa...study is published online Nov. 23 in Cancer , a j...ding indicates that although BMI and co-morbidity ...
(Date:11/23/2009)...CORVALLIS, Ore. A string of recent discoveries ab...renewed interest in this multi-purpose nutrient, i...ho are deficient in it, spurred research and even ...ic." , On issues ranging from the health of your...even vulnerability to influenza, vitamin D is now ...
Breaking Biology News(10 mins):Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 1Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 2Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 3Photos 3A FDA Approves 12 Month Labeling Update for EVOLENCE 28R 29 Collagen Based Facial Filler 12508 4Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 1Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17 2009 48147 2(Date:11/25/2009)...ors often plagued by neurological symptoms, study ... News) -- Neurological side effects are among the ... testicular cancer who were treated with cisplatin...he study included 1,409 Norwegian men treated for ... who took part in a follow-up survey conducted fro...
(Date:11/25/2009)..., LittleImprovementShownforthe4thStraightYear ...Today,LungCancerAlliance-Georgia(LCA-GA)issuedthe ...essmentofprogressbeingmadeagainstthislethaldisease...liance(LCA),theonlynationalorganizationdedicatedex...gwithoratriskforlungcancer. ,, (Logo: http://ww...
(Date:11/25/2009)...e, disks placed under the skin kill tumor cells, s...hDay News) -- A cancer vaccine delivered in a fing...mice, a new study reports. , The method uses po... loaded with tumor-specific antigens and implanted...attack tumors. The Harvard University scientists w...
(Date:11/25/2009)... BioSpace.com, the premier reso...eiled the third edition of the BioForest™ Ho... Englewood, CO (Vocus) November 25, 2009 -- Bi...careers and information, unveiled the third editio...ning., , , , ,This regional campaign is a promoti...
(Date:11/25/2009)..., SALTLAKECITY,Nov.25/PRNewswire/--dazzlesmile,llc...ww.optimalhealthscience.com havefileda67-pagefeder...ogle.com,Inc.,JesseWillms,FarendServicesLimited,an...heUnitedStatesDistrictCourtfortheDistrictofUtah,al...dazzlesmile(TM)brandedteethwhiteningproducts,viola...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2[0] Long-Term Problems Linked to Testicular Cancer Chemo[0] Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer[2] Implantable Cancer Vaccine Shows Promise[1] BioSpace Showcases Leading Life-Science Companies in the Northwest[0] dazzlesmile Sues Epic Advertising and Jesse Willms
hedgingMerrillbuilderdownplaysdiamondsRubyrearseligiblebackedhighlightrigorscaptivatedPretextingexpects
Other Tagspossible 2possible 3possible 4possible 5possible 6possible 7possible 8possible 9possible 10chicken 2chicken 3chicken 4chicken 5chicken 6chicken 7chicken 8chicken 9chicken 10from 2from 3from 4from 5from 6from 7from 8from 9from 10saving 2saving 3saving 4saving 5saving 6saving 7saving 8saving 9saving 10life 2life 3life 4life 5life 6life 7life 8life 9life 10death 2death 3death 4death 5death 6death 7death 8death 9death 10extra 2extra 3extra 4extra 5extra 6rewarding 2predicted 2predicted 3predicted 4predicted 5predicted 6predicted 7predicted 8predicted 9
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |